Chen Michael X, Kuehne Nathan, Mattman Andre, Liu Jun, Van der Gugten Grace, Wright Bruce
Department of Laboratory Medicine, Pathology and Medical Genetics, Island Health, Victoria, British Columbia, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
J Mass Spectrom Adv Clin Lab. 2022 Mar 28;24:43-49. doi: 10.1016/j.jmsacl.2022.03.002. eCollection 2022 Apr.
Hepcidin is a hormone that regulates systemic iron homeostasis. Serum hepcidin levels are under the influence of various stimuli, particularly inflammation and renal dysfunction. The measurement of hepcidin in circulation is a potentially useful clinical tool in the diagnosis, monitoring and treatment of iron metabolism disorder, although clinical interpretation of hepcidin level remains difficult. We evaluated he diagnostic potential and limitations of hepcidin-25 by investigating its relationship with iron and hematological indices, inflammation, and renal dysfunction.
This retrospective study included 220 adult patients not requiring dialysis. Variations of biologically active hepcidin-25 were examined using a mass spectrometry-based assay in various inflammatory and renal states. The log[hepcidin]:log[ferritin] ratio was calculated as an hepcidin index.
In 220 adult patients not requiring dialysis, variation in hepcidin-25 level was significantly larger once CRP exceeded 10 mg/l (p < 0.001). Inflammation was not a determinant of hepcidin-25 in the setting of renal dysfunction. Hepcidin-25 median (7.37 nM) and variance were significantly higher (p < 0.001), once estimated glomerular filtration rate (eGFR) dropped below 30 ml/min/1.73 m. The log[hepcidin]:log[ferritin] index normalized hepcidin levels. Patients with iron deficiency have a notably lower index when compared to controls (-0.66 vs 0.3).
Severe renal dysfunction (eGFR < 30) affected hepcidin-25 expression and clearance to variable degree between individuals. Although, hepcidin-25 testing is not warranted in patients with infection, inflammatory autoimmune conditions (CRP > 10 mg/l) and/or severe renal dysfunction (eGFR < 30), the hepcidin index may serve as a potential biomarker for iron deficiency in complex cases.
铁调素是一种调节全身铁稳态的激素。血清铁调素水平受多种刺激因素影响,尤其是炎症和肾功能不全。循环中铁调素的检测在铁代谢紊乱的诊断、监测和治疗中是一种潜在有用的临床工具,尽管对铁调素水平的临床解读仍然困难。我们通过研究铁调素-25与铁及血液学指标、炎症和肾功能不全的关系,评估了其诊断潜力和局限性。
这项回顾性研究纳入了220名不需要透析的成年患者。在各种炎症和肾脏状态下,使用基于质谱的检测方法检测生物活性铁调素-25的变化。计算log[铁调素]:log[铁蛋白]比值作为铁调素指数。
在220名不需要透析的成年患者中,当CRP超过10mg/l时,铁调素-25水平的变化显著更大(p<0.001)。在肾功能不全的情况下,炎症不是铁调素-25的决定因素。一旦估计肾小球滤过率(eGFR)降至30ml/min/1.73m²以下,铁调素-25中位数(7.37nM)和方差显著更高(p<0.001)。log[铁调素]:log[铁蛋白]指数使铁调素水平正常化。与对照组相比,缺铁患者的指数明显更低(-0.66对0.3)。
严重肾功能不全(eGFR<30)在个体之间对铁调素-25的表达和清除有不同程度的影响。尽管对于感染、炎症性自身免疫疾病(CRP>10mg/l)和/或严重肾功能不全(eGFR<30)的患者,不建议进行铁调素-25检测,但铁调素指数可能作为复杂病例中铁缺乏的潜在生物标志物。